- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Sep 17, 2012
Regulation
Debating access in Germany
AMNOG statistics less important than whether drugs bypass Germany
BioCentury | Jul 16, 2012
Regulation
Rating innovation
Comparing how France, Germany define pharma innovation for reimbursement
BioCentury | Dec 5, 2011
Clinical News
Rasitrio aliskiren/amlodipine/hydrochlorothiazide regulatory update
BioCentury | Sep 19, 2011
Regulation
Bypassing Germany
BI-Lilly, Novartis bypass Germany with 2 new drugs; blame AMNOG pricing reforms
Items per page:
1 - 10 of 14